As competition in immuno-oncology hots up, in New York, a biotech startup called Rgenix has entered the fray with RGX-104, a small molecule currently entering Phase I.
Chief executive and scientific co-founder Masoud Tavazoie spoke to The Pharma Letter from his office in Manhattan about the future of immuno-oncology and his young company’s bid to develop a first-in-class therapy that targets cancer.
Rgenix
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze